Format

Send to

Choose Destination
Br J Haematol. 2019 Jun;185(6):1043-1054. doi: 10.1111/bjh.15763. Epub 2019 Jan 25.

From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.

Author information

1
Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, UK.
2
European Research Initiative for ALK-related malignancies (www.erialcl.net), Cambridge, UK.
3
Department of paediatric oncology, Addenbrooke's Hospital, Cambridge, UK.
4
Division of Pediatric Hematology-Oncology, Children's Hospital of the Kings Daughter, Norfolk, Virginia, USA.

Abstract

Anaplastic large cell lymphoma (ALCL) is a T cell Non-Hodgkin Lymphoma that mainly presents in paediatric and young adult patients. The majority of cases express a chimeric fusion protein resulting in hyperactivation of anaplastic lymphoma kinase (ALK) as the consequence of a chromosomal translocation. Rarer cases lack expression of ALK fusion proteins and are categorised as ALCL, ALK-. An adapted regimen of an historic chemotherapy backbone is still used to this day, yielding overall survival (OS) of over 90% but with event-free survival (EFS) at an unacceptable 70%, improving little over the past 30 years. It is clear that continued adaption of current therapies will probably not improve these statistics and, for progress to be made, integration of biology with the design and implementation of future clinical trials is required. Indeed, advances in our understanding of the biology of ALCL are outstripping our ability to clinically translate them; laboratory-based research has highlighted a plethora of potential therapeutic targets but, with high survival rates combined with a scarcity of funding and patients to implement paediatric trials of novel agents, progress is slow. However, advances must be made to reduce the side-effects of intensive chemotherapy regimens whilst maintaining, if not improving, OS and EFS.

KEYWORDS:

Children's Oncology Group; European Inter-Group for Childhood non-Hodgkin Lymphoma; anaplastic large cell lymphoma; anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitors

PMID:
30681723
DOI:
10.1111/bjh.15763

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center